Table of Appendix Contents

A


Basal (75)
R = 0.324
P = 4.51x10-3
Her2 (24)
R = -0.193
P = 0.366
Lum A (89)
R = 0.001
P = 1
Lum B (49)
R = 0.137
P = 0.348
Normal (29)
R = -0.445
P = 0.015
y-axis: Log2 of GLUT1 gene (SLC2A1)
X-axis: Log2 of MIG-6 gene (ERRFI1)

B


TNBC (58)
R = 0.125
P = 0.348
Her2 (14)
R = 0.343
P = 0.229
Lum A (145)
R = -0.039
P = 0.641
Lum B (87)
R = -0.083
P = 0.446
Lum/Her (39)
R = 0.221
P = 0.176
y-axis: Log2 of GLUT1 gene (SLC2A1)
X-axis: Log2 of MIG-6 gene (ERRFI1)

A


Pearson's coefficient r value
1.0
0.8
0.6
0.4
0.2
0.0
Patient no. 1 to 85

B


Percentage (%)
100
80
60
40
20
0
73/85
11/85
1/85
weak
moderate
strong


BT549
MDA-MB-231
PC9
H3255
- + - + - + - +
Gefitinib
pMIG-6 (Y394/Y395)
50
MIG-6
50
β-actin

Appendix Figure Legends

Appendix Figure S1. Correlation of MIG-6 and GLUT1 expression at the mRNA level. (A and **B)** Scatterplot analysis for the correlation between GLUT1 and MIG-6 mRNA expression in various breast cancer subtypes in the Bertucci **(A)** and Servant **(B)** datasets of breast cancer carcinomas, analyzed using Illumina HumanWG-6_v3 Arrays. The gene expression levels are determined using the R2 platform. Pearson's correlation coefficient (r) and p values are shown for each analysis.

Appendix Figure S2. Immunofluorescence multiplex assay for colocalization of MIG-6 and HIF1α protein expression in TNBC tumor specimens. (A) The colocalization coefficiency of MIG-6 and HIF1α in 85 TNBC tumors is determined by Pearson's Correlation Coefficient (*r*) value using the JaCoP plugin from ImageJ software. (**B**) The bar graph shows the percentage of tumors with a weak, moderate, or strong correlation between MIG-6 and HIF1α protein expression (n=85). $r < 0.3$, weak correlation; $0.3 \leq r < 0.7$, moderate correlation; $r \geq 0.7$, strong correlation.

Appendix Figure S3. MIG-6 tyrosine phosphorylation at Y394/Y395 in TNBC and lung cancer cells. Immunoblotting analysis for MIG-6 tyrosine phosphorylation at Y394/Y395 in TNBC and lung cancer cells in the absence and presence of gefitinib.